$1.44
0.021.41%
At Close: -
$1.44
0.00500.35%
After Hours: Jul 26, 4:56 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Spero Therapeutics (NASDAQ:SPRO) Stock, Analyst Ratings, Price Targets, Forecasts
Spero Therapeutics Inc has a consensus price target of $5.67 based on the ratings of 6 analysts. The high is $8 issued by Evercore ISI Group on September 23, 2022. The low is $2 issued by Berenberg on May 20, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on May 16, 2024, March 18, 2024, and November 14, 2023, respectively. With an average price target of $7 between HC Wainwright & Co., there's an implied 386.11% upside for Spero Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Evercore ISI Group
Berenberg
1calculated from analyst ratings
Analyst Ratings for Spero Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/16/2024 | Buy Now | 386.11% | HC Wainwright & Co. | Raghuram Selvaraju | → $7 | Reiterates | Buy → Buy | Get Alert |
| 04/04/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen | — | Reiterates | → Overweight | Get Alert |
| 03/18/2024 | Buy Now | 386.11% | HC Wainwright & Co. | Raghuram Selvaraju | → $7 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2023 | Buy Now | 386.11% | HC Wainwright & Co. | Raghuram Selvaraju | → $7 | Reiterates | Buy → Buy | Get Alert |
| 09/05/2023 | Buy Now | 386.11% | HC Wainwright & Co. | Raghuram Selvaraju | → $7 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2023 | Buy Now | 386.11% | HC Wainwright & Co. | Raghuram Selvaraju | $6 → $7 | Maintains | Buy | Get Alert |
| 08/01/2023 | Buy Now | 316.67% | HC Wainwright & Co. | Raghuram Selvaraju | → $6 | Reiterates | Buy → Buy | Get Alert |
| 07/20/2023 | Buy Now | 316.67% | HC Wainwright & Co. | Raghuram Selvaraju | → $6 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2023 | Buy Now | 316.67% | HC Wainwright & Co. | Raghuram Selvaraju | → $6 | Reiterates | → Buy | Get Alert |
| 09/26/2022 | Buy Now | 316.67% | HC Wainwright & Co. | Raghuram Selvaraju | $7 → $6 | Maintains | Buy | Get Alert |
| 09/23/2022 | Buy Now | 455.56% | Evercore ISI Group | Josh Schimmer | $2 → $8 | Upgrade | In-Line → Outperform | Get Alert |
| 08/15/2022 | Buy Now | 386.11% | HC Wainwright & Co. | Raghuram Selvaraju | $10 → $7 | Maintains | Buy | Get Alert |
| 05/23/2022 | Buy Now | 594.44% | HC Wainwright & Co. | Raghuram Selvaraju | $37 → $10 | Maintains | Buy | Get Alert |
| 05/20/2022 | Buy Now | 38.89% | Berenberg | Esther Hong | → $2 | Downgrade | Buy → Hold | Get Alert |
| 05/17/2022 | Buy Now | 247.22% | Cantor Fitzgerald | Louise Chen | $27 → $5 | Maintains | Overweight | Get Alert |
| 05/04/2022 | Buy Now | — | Cowen & Co. | Ritu Baral | — | Downgrade | Outperform → Market Perform | Get Alert |
| 05/04/2022 | Buy Now | 38.89% | Evercore ISI Group | Josh Schimmer | $40 → $2 | Downgrade | Outperform → In-Line | Get Alert |
| 04/18/2022 | Buy Now | 2469.44% | HC Wainwright & Co. | Raghuram Selvaraju | $43 → $37 | Maintains | Buy | Get Alert |
| 03/21/2022 | Buy Now | 2886.11% | HC Wainwright & Co. | Raghuram Selvaraju | $40 → $43 | Maintains | Buy | Get Alert |
| 10/01/2021 | Buy Now | — | Oppenheimer | Kevin DeGeeter | — | Downgrade | Outperform → Perform | Get Alert |
FAQ
What is the target price for Spero Therapeutics (SPRO) stock?
The latest price target for Spero Therapeutics (NASDAQ:SPRO) was reported by HC Wainwright & Co. on May 16, 2024. The analyst firm set a price target for $7.00 expecting SPRO to rise to within 12 months (a possible 386.11% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Spero Therapeutics (SPRO)?
The latest analyst rating for Spero Therapeutics (NASDAQ:SPRO) was provided by HC Wainwright & Co., and Spero Therapeutics reiterated their buy rating.
When was the last upgrade for Spero Therapeutics (SPRO)?
The last upgrade for Spero Therapeutics Inc happened on September 23, 2022 when Evercore ISI Group raised their price target to $8. Evercore ISI Group previously had an in-line for Spero Therapeutics Inc.
When was the last downgrade for Spero Therapeutics (SPRO)?
The last downgrade for Spero Therapeutics Inc happened on May 20, 2022 when Berenberg changed their price target from N/A to $2 for Spero Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Spero Therapeutics (SPRO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Spero Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Spero Therapeutics was filed on May 16, 2024 so you should expect the next rating to be made available sometime around May 16, 2025.
Is the Analyst Rating Spero Therapeutics (SPRO) correct?
While ratings are subjective and will change, the latest Spero Therapeutics (SPRO) rating was a reiterated with a price target of $7.00 to $7.00. The current price Spero Therapeutics (SPRO) is trading at is $1.44, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.